Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Bayer shareholder Union Investment says CEO should stay on

Published 03/28/2022, 02:14 PM
Updated 03/28/2022, 02:16 PM
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

FRANKFURT (Reuters) - Bayer (OTC:BAYRY) shareholder Union Investment on Monday came out in support of the drugmaker's chief executive serving out his full term after the CEO came under renewed pressure over the company's performance.

The support of Germany's Union Investment, which is a top-20 shareholder, for CEO Werner Baumann to see out his contract to 2024 comes after Bloomberg reported over the weekend that Singapore state investor Temasek, another large shareholder, was pushing for Baumann's removal.

Bloomberg, which cited people familiar with the matter, said Temasek had concerns about Bayer’s operating performance under Baumann and the company’s lack of succession planning.

Janne Werning, Union Investment's head of capital markets and stewardship, said in a statement he was satisfied for Baumann to step down as planned in two years because, while Bayer's 2018 takeover of seed maker Monsanto (NYSE:MON) was an unnecessary financial risk, the CEO should stay on to oversee recent positive changes.

"Initial progress is visible and to bring forward his departure by cancellation of his contract would only sow chaos," Werning said.

He cited improvement at the Crop Science division, driven by higher produce prices, and a recent slew of drug development transactions as among promising signs.

In 2020, Baumann's contract was extended until 2024. He said at the time he was initially offered a longer term but that he had opted for a shorter duration due to personal plans.

Bayer's executive board won clear votes of confidence from shareholders at last year's annual general meeting (AGM) and in 2020, but suffered a rebuke in 2019 over the handling of lawsuits related to Monsanto's weedkiller Roundup, which has cost Bayer billions of dollars to settle.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Another shareholder, Swiss investment manager Alatus Capital SA, this month filed a motion for Bayer's AGM scheduled for April 29, to vote against ratifying the actions of the executive board.

Bayer responded at the time by saying the motion was unjustified because the operating business was developing positively and progress had been made in the Roundup litigation.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.